Company intelligence / Profile preview

Invictus BioPharma

Sydney, New South Wales, Australiamontauktx.com ↗

Ownership: Private
Development stage: Phase 3

Overview

Invictus BioPharma developed a platform for transmucosal delivery of tocotrienols. As of early 2022, two drug candidates were commencing Phase II clinical trials targeting NAFLD/NASH and pancreatic cancer. Two additional prodrug candidates were in preclinical optimization with Monash Institute collaborations.

Therapeutic areas: GastroenterologyOncology
Modalities: Small molecules (tocotrienols and tocotrienol prodrugs)Nutraceuticals
Industry: Biotech

Drug pipeline

3 assets

Iomab-B

Phase 3

Indications: Acute Myeloid Leukemia

2 more assets in the full pipeline.

Request access →

Partnerships

Collaboration with Professor Christopher Porter’s group at Monash Institute of Pharmaceutical Sciences for research optimization

Beyond the preview

Go deeper on Invictus BioPharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Invictus BioPharma.

Explore the full profile